Related Experiment Videos
[Bronchogenic carcinoma invading the thoracic wall. The results of surgical treatment]
E Forni1, G Volpato, F Meriggi
1Università degli Studi di Pavia, Clinica Chirurgica II, I.R.C.C.S. Policlinico S. Matteo.
Minerva Medica
|July 1, 1989
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Gemox: a widely useful therapy against solid tumors-review and personal experience.
Journal of chemotherapy (Florence, Italy)·2010
Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.
Current gerontology and geriatrics research·2010
The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?
Reviews on recent clinical trials·2009
Anti-EGFR therapy in colorectal cancer: how to choose the right patient.
Current drug targets·2009
The Renaissance of platinum-based chemotherapy for metastatic breast cancer.
Journal of chemotherapy (Florence, Italy)·2008
The potential role of pemetrexed in gastrointestinal cancer.
Chemotherapy·2007
Celiac disease incidence after COVID-19 infection.
Minerva medica·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026